Access win for HIV patients in sub-Saharan Africa - European Medical Journal

Access win for HIV patients in sub-Saharan Africa

1 Mins
EMJ GOLD
Words by GOLD newsdesk

The injectable HIV treatment cabotegravir is set to become more widely available in sub-Saharan Africa following a new licensing agreement between developer ViiV Healthcare and the United Nations-backed public health organisation Medicines Patent Pool.

The agreement will improve access to the treatment in the least developed, low-income and lower middle-income countries in the region by allowing local manufacturers to develop and supply generic versions of the drug.

“[This] announcement represents a potentially game-changing moment in HIV prevention,” said Deborah Waterhouse, CEO, ViiV Healthcare. “Enabling at-scale access to generic cabotegravir LA for PrEP could play a significant role in averting the transmission of HIV, particularly amongst women and adolescent girls and help end the HIV epidemic.”

Cabotegravir long-acting (LA) is an injectable form of pre-exposure prophylaxis, otherwise known as PrEP, which is the world’s first long-acting HIV prevention medicine. Research has found that PrEP reduces the risk of getting sexually-transmitted HIV by about 99% when taken as prescribed.

The new licensing deal is part of a long-standing partnership between ViiV Healthcare and Medicines Patent Pool, which is focused on facilitating the manufacture and sale of generic versions of the pharma company’s medicines in low- and middle-income countries.

There are as many as 1.5 million new cases of HIV worldwide every year, and increasing access to an effective long-acting prevention option has the potential to bring the healthcare community closer to its goal of ending the epidemic.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given